Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation.

However, in terms of brain metastasis status, although the mPFS in patients without brain metastases before treatment with osimertinib was more than twice as high as that in those suffering from brain metastases (13.5 months versus 6.4 months) and the Kaplan–Meier curves also showed a trend favoring patients without brain metastases, however, there was no statistically significant difference between them.

also in 53,322 other papers